scholarly journals Diabetic: A Comparative Study

2017 ◽  
Vol 4 (1) ◽  
pp. 19-26
Author(s):  
Alok Dhungel ◽  
Tariq Wassem ◽  
Kshitiz Upadhyay-Dhungel
Keyword(s):  
Comparative Study ◽  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Diabetic Patients ◽  
Female Group ◽  
Type Ii ◽  
Cross Sectional ◽  
Significant Difference ◽  
Function Test ◽  
Group A

Background and Objectives: Type II diabetes mellitus (DM) is particularly common medical disorder and is leading cause of morbidity worldwide. The complication of DM is due to micro or macro vascular damage. The presence of an extensive microvascular circulation and abundant connective tissue in the lungs raises the possibility that lung tissue may be a target organ in diabetic patients and thus pulmonary function test can be affected by DM. This study was designed to compare pulmonary function test between Type II diabetic and non-diabetic individuals; and, with the duration of DM.Material and Methods: This cross sectional comparative study was conducted at King Edward Medical University, Lahore Pakistan. Total sample consist of 91 diabetic and 91 non-diabetic grouped as group A and group B. FEV1, FVC, FEV1/FVC ratio, and PEFR were compared within two groups and with the duration of DM.Results: Total 182 sample with mean age 53.1±5.90 years, with 91(50%) male and 91(50%) female. Group A and B had 91(50%) sample each. Mean value of FVC, FEV1 and PEFR showed statistically significant difference among the both group. Mean of FVC decreases significantly with the increasing duration of DM; although, is not significant with FEV1, FEV1/FVC ratio, and PEFR.Conclusion: Diabetic group showed significantly impaired pulmonary functions test as FEV1, FVC, and PEFR as compare to non-diabetic group.Janaki Medical College Journal of Medical Sciences (2016) Vol. 4 (1): 19-26

Correlation of Tracheal Cross-sectional Area with Parameters of Pulmonary Function Test in COPD

1999 ◽  
Vol 46 (5) ◽  
pp. 628 ◽  
Author(s):  
Chan Ju Lee ◽  
Jae Ho Lee ◽  
Jae Woo Song ◽  
Chul Gyu Yoo ◽  
Young Whan Kim ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Cross Sectional Area ◽  
Sectional Area ◽  
Cross Sectional ◽  
Function Test

RESPIRATORY SYMPTOMS AND PULMONARY FUNCTION TEST AMONG SALON EMPLOYEES IN JEDDAH, SAUDI ARABIA: CROSS-SECTIONAL STUDY

CHEST Journal ◽  
2018 ◽  
Vol 154 (4) ◽  
pp. 791A
Author(s):  
AHMED ALJOHANEY ◽  
SHAHAD DAALI ◽  
HANOUF AL-JUAID ◽  
MAYSAA AGEEL ◽  
SAMAHER SUKKAR ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Respiratory Symptoms ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Function Test

Changes of pulmonary function test and development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 530-530
Author(s):  
Kwon-Oh Park ◽  
Jae-Lyun Lee ◽  
Jin-Hee Ahn ◽  
In Gab Jeong ◽  
Cheryn Song ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Pulmonary Function ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Pulmonary Function Test ◽  
Renal Cell ◽  
Repeated Measures ◽  
Alveolar Volume ◽  
Significant Difference ◽  
Function Test

530 Background: The aim of this study was to evaluate the changes of pulmonary function test (PFT) during everolimus treatment and to assess whether the change of PFT is associated with the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma. In addition, we tried to determine whether everolimus-associated pneumonitis could affect the efficacy of everolimus. Methods: Patients with mRCC who had received everolimus (10 mg dose once daily) after failure to VEGF-TKI treatment and underwent baseline PFT with regular PFT follow up were included in this study. The diffusing capacity divided by the alveolar volume (DLCO/VA) was used among various parameters of PFT. Repeated-measures ANOVA was used to describe changes of DLCO/VA. A Cox proportional hazard model with pneumonitis onset as a time-dependent covariate used to assess the prognostic role of pneumonitis. Results: This study included 36 patients. Nine patients (30%) developed everolimus-associated pneumonitis (pneumonitis group) and 27 were included in non-pneumonitis group. Five patients (14%) among pnemonitis group were symptomatic. The baseline DLCO/VA of patients was 90.0%. It decreased to 80.2%, 76.4%, 76.0%, and 72.1% after everolimus treatment of 6, 12, 18, and 24 weeks, respectively. DLCO/VA declined significantly as the treatment duration becomes longer (p < 0.001). There was no significant difference in change of DLCO/VA between patients with pneumonitis and those without pneumonitis (p =0.435). On time-variant Cox analysis, the decrease of DLCO/VA was not correlated with the efficacy of everolimus in terms of progression free survival (PFS, HR=1.0, p=0.94) and overall survival (OS, HR=0.98, p=0.18), while development of pneumonitis was associated with poor PFS (HR=4.60, p=0.005). Conclusions: Although the eveolimus treatment decreased DLCO/VA, the decline of DLCO/VA was not associated with the development of pneumonitis. Changes in DLCO/VA were not related with efficacy of everolimus, while the development of pneumonitis was a prognostic factor for PFS.

Sign in / Sign up

Export Citation Format

Share Document